Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2012 /
Phase III MISSION trial: Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer

28th Sep - 2nd Oct 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.10.12
Views: 2825

Dr Tony Mok – The Chinese University of Hong Kong

Dr Tony Mok talks to ecancer at the 2012 ESMO meeting in Vienna about a randomised phase III study that looked at sorafnib in combination with the best supportive care in selected populations as third and fourth line therapy.

Overall the MISSION study showed only slight improvement in progression free survival in patients with non-small cell lung cancer. Ultimately the results were deemed as negative.

Although negative in terms of survival, Dr Mok expressed that the study provided information on small populations that had better survival compared to populations with EGF 1 mutation. Also, the study showed results that concluded that KRAS is not an effective biomarker for sorafnib.


Filming supported by Amgen

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation